Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
RESEARCH TOOLSreports
Holding LXRX?
Track your performance easily
LXRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.62 - $3.73
Previous Close$0.71
Volume7.37M
Average Volume (3M)4.11M
Market Cap
$261.58M
Enterprise Value$99.89M
Total Cash (Recent Filing)$258.37M
Total Debt (Recent Filing)$99.90M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Mar 12, 2025EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding361,492,295
10 Day Avg. Volume6,067,542
30 Day Avg. Volume4,113,305
Standard Deviation0.31
R-Squared0.03
Alpha0.00158
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.46
Price to Sales (P/S)49.80
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue26.72
Enterprise Value/Gross Profit89.27
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$4.30Price Target Upside501.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Lexicon Pharmaceuticals News
PremiumCompany Announcements
Lexicon Pharmaceuticals Appoints Ivan Cheung to Board
PremiumCompany Announcements
Lexicon Pharmaceuticals Reports Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Clinical AdvancementsLX9211 is positioned as a potential first-in-class non-opioid treatment with disease-modifying potential for diabetic peripheral neuropathic pain (DPNP).
Product DevelopmentSotagliflozin's therapeutic activity has the potential to address a broad range of cardiometabolic complications with growing market opportunities.
Strategic GrowthThe commercial growth potential of INPEFA and late-stage opportunities for sotagliflozin and LX9211 position Lexicon as a valuable, fully integrated biopharmaceutical company.
Bears Say
Financial Performance3Q24 Inpefa sales were $1.7M, below expectations and consensus.
Market CompetitionPrescription rates and sales could be constrained or delayed considering that HF is a crowded space among the big players.
Regulatory ChallengesThe FDA decision for ZYNQUISTA follows an overall unfavorable vote from the committee and a not-so-positive sentiment from the FDA.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.62 and its highest was $3.73 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Currently, no data Available
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Mar 12, 2025 which is in 79 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.163 by -$0.017.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -$0.13.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 361,492,300 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.163. Following the earnings report the stock price went down -8.403%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Among the largest hedge funds holding Lexicon Pharmaceuticals’s share is Woodline Partners LP. It holds Lexicon Pharmaceuticals’s shares valued at 2M.
---
Lexicon Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.30 (501.65% Upside)
$4.30 (501.65% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.47%
12-Months-Change
Fundamentals
Return on Equity
-135.14%
Trailing 12-Months
Asset Growth
16.15%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
---
LXRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in clinical development and strategic partnerships, particularly the resubmission of the NDA for ZYNQUISTA and the Viatris agreement. However, challenges were noted with modest sales growth for INPEFA and increased financial losses. The FDA Advisory Committee's negative vote on ZYNQUISTA's benefits versus risks is a notable setback.Read More>---
LXRX Stock 12 Month Forecast
Average Price Target
$4.30
▲(501.65% Upside)
Technical Analysis
Best Analysts Covering LXRX
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-16.74%
reiterated a buy rating 27 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -16.74% per trade.
---